Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...

Read about Chularat Hospital, Ramsay Health Care and more in the latest Market Talks covering the Health Care sector.

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GL ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...

The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...

The Biden administration proposed a rule to let Medicare and Medicaid cover obesity drugs like Ozempic. Millions would ...

Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.

The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and ...

The plans from the Department of Health and Human Services come on the heels of criticism Ozempic and other weight loss medications received by RFK Jr.

And those who follow the Biden administration’s move to expand access to anti-obesity medications such as Ozempic and Wegovy, which are produced by the drugmaker Novo Nordisk, and Mounjaro and ...